Patent EA-002423-B1 (EA)
Title: Antimicrobal prevention and tretment of human immunedeficiency virus and other infectious diseases
IPC: A61K38/28
Filed: 1998-03-24
Abstract: 1 A composition comprising a nutrient and a plant, characterized in that the nutrient comprises folic acid, the plant comprises a herbaceous botanical of the genus Echinacea, and the Echinacea comprises Echinacea purpurea. 2. A composition as claimed in Claim 1, characterized in that the composition further includes a second plant comprising a herbaceous botanical of the genus Commiphora. 3. A composition as claimed in Claim 2, characterized in that the Commiphora comprises a species consisting of Commiphora myrrha, Commiphora molmol, or Commiphora erythraea. 4. A composition as claimed in any one of the preceding in Claims 2-3, characterized in that the Commiphora comprises Commiphora myrrha. 5. A composition as claimed in any one of the preceding Claims, characterized in that the composition comprises by weight: from about 2% to about 12% folic acid; from about 40% to about 60% Echinaoea purpurea and Commiphora myrrha; and from about 20% to about 60% water. 6. A composition as claimed in any one of the preceding Claims 3-5, characterized in that the ratio of Commiphora myrrha to Echinacea purpurea ranges from about 1:2 to about 1:4. 7. A composition as claimed in any one of the preceding Claims, characterized in that the composition further includes from about 0.02% to less than 0.26% by weight of a quaternary ammonium salt surfactant. 8. A composition as claimed in Claim 7 wherein the quaternary ammonium salt surfactant comprises benzalkonium chloride. 9. The use of a composition as claimed in any one of the preceding Claims in the preparation of a product for treatment or prevention of diseases selected from the group consisting of virus influenza, virus parainfluenza, virus encephalitis, viral meningitis, bacteria encephalitis, bacteria meningitis and cellulites, as well as disease cased by human immunodeficiency virus (HIV), herpes simplex virus 1, herpes simplex virus 2, varicella zoster virus (herpes zoster), cytomegalovirus, Epstein-Barr virus, papilloma virus, adenovirus, arbovirus, arenavirus, picornavirus, coronavirus, syncytial virus, staphylococci, streptococci, mycobacteria, or anaerobic bacilli. 10. A method for use in treating diseases, comprising the steps of:  inhibiting microbial infections from microbe-causing diseases by applying microbe inhibitors systemically, orally or topically to a person or animal with a microbial infected region; and  maintaining the microbe inhibitors on the infected region to help decrease external symptoms and physical manifestations of the infection substantially about the infected region; the microbe inhibitors comprising antimicrobial isolates of at least a portion of a first plant and a second plant; the first plant comprises a herbaceous botanical of the genus Echinacea, and the Echinacea comprises Echinacea purpurea; the second plant comprises a herbaceous botanical of the genus Commiphora, the Commiphora being a species comprising Commiphora myrrha, Commiphora molmol, or Commiphora erythrea; the microbe inhibitors are viral inhibitors or bacterial inhibitors; the microbe causing-diseases are viral diseases or bacterial diseases; viral diseases selected from the group consisting of virus influenza, virus parainfluenza, virus encephalitis, viral meningitis, as well as disease cased by human immunodeficiency virus (HIV), herpes simplex virus 1, herpes simplex virus 2, varicella zoster virus (herpes zoster), cytomegalovirus, Epstein-Barr virus, papilloma virus, adenovirus, arbovirus, arenavirus, picornavirus, coronavirus, and syncytial virus, bacterial diseases are cellulites, bacteria encephalitis and bacteria meningitis and disease cased by staphylococci, streptococci, mycobacteria, or anaerobic bacilli. 11. A method as claimed in Claim 10, characterized in that: the microbe inhibitors are applied on an external portion of an animal comprising a dog, cat, bird, horse, cow, sheep, swine, farm animal, or rodent; and the microbe inhibitors arc applied by directly contacting the infected region of the animal with the microbe inhibitors. 12. A method as claimed in Claim 11, characterized in that: the applying comprises syringing, sublingual, intranural, or dispensing; and/or the infected area comprises lump nodes, lymphatic system, T-cells, oral mucosa, nasal mucosa, vaginal tissue, labial tissue, anal tissue, perianal tissue, lips, cutaneous tissue, ocular tissue, conjunctive, or eyelids; and/or the microbe inhibitors are applied into the rectum or vagina of a person or animal with the infected region. 13. A method as claimed in any one of the preceding Claims 10-12, characterized in that: the microbe inhibitors are applied systemically or orally with a nutrient; and the nutrient comprises folacin (folic acid), vitamin A, vitamin D, vitamin E, vitamin K, vitamin B complex, vitamin Bl, vitamin B2, vitamin B5, vitamin B12, or vitamin B15. 14. A method as claimed in any one of the preceding Claims 10-12, characterized in that: the microbe inhibitors are applied topically on the infected region with a surfactant and a carrier; the surfactant comprises a quaternary ammonium salt surfactant - dimethylbenzylammonium chloride, benzalkonium halide (benzalkonium bromide, benzalkonium chloride), alkylbenzyldimethylammonium chloride, alkyldimethylethylbenzylammonium chloride, n-alkyldimethylbenzylammonium chloride, diisobutylphenoxyethoxethyldimethylammonium chloride, n-dimethylbenzylammonium chloride, octyldecyldimethylammonium chloride, didecyldimethylammonium chloride, dioctyldimethylammonium chloride, diakyldimethylammonium chloride, octyldecylidimethylammonium chloride, lauryldimethylbenzylammonium chloride, o-benzyl-p-chlorophenol, dideryldimethylammonium chloride, doctyldimethylammonium chloride, alkyldimethylbenzylammonium chloride, or alkylbenzyldimethylammonium chloride; and/or the carrier comprises an aqueous carrier, water, glycerin, mineral oil, silica oxide, talc, natural resins, synthetic resins, pyrethrum, thiocyannates, phthalates, cottonseed oil, coconut oil, pine oil, vegetable oil, seed oil, nut oil, fish oil, animal oil, alcohol, corn meal, beeswax, carnauba wax, beta carotene, garlic oil, camphor oil, soluble vitamins, soluble minerals, rape seed oil, olive oil, lipsomes, ascorbic acid, primrose oil, pyknogenol, grape seed oil, lanolin, collagen, herbs, aloe vera, bee pollen, royal jelly, chondroitin sulfate, sea vegetables, fatty acids, lecithin, bioflavinoids, grain oil, grain powder, algae, vinegar, acidophilus, glandulars, aminoacids, psyllium, plant derivatives, fruit derivatives, or a sterile carrier. 15. A method as claimed in any one of the preceding Claims 10-14, characterized in that the microbe inhibitors are applied or maintained on the infected region from 4 to 12 times per day for a period of 4 to 18 days. 16. A method as claimed in any one of the preceding Claims 10-15, characterized in that the Commiphora comprises Commiphora myrrha; and the ratio of Commiphora myrrha to Echinecea purpurea ranges from 1:2 to 1:4. 17. A method as claimed in any one of the preceding Claims 10-16, characterized in that the microbe inhibitors are applied or maintained on the infected region with folic acid and water in the following proportion by weight: from about 40% to about 60% microbe inhibitors, the microbe inhibitors comprising Echinacea purpurea and Commiphora myrrha; from about 2% to about 12% folic acid; and from about 20% to about 60% water. 18. A method as claimed in any one of the preceding Claims 10-17, characterized in that the microbe inhibitors are applied or maintained on the infected region with from about 0.02% to less than 0.26% by weight of benzalkonium chloride.